… , we have investigated the pharmacokinetic characteristics of epoetin beta after the initial …
once-weekly repeated dose subcutaneous administration in anemic lung cancer patients. The …

… of reports on pharmacokinetics (PK) with higher dose are available. We carried out the
PK and pharmacodynamic study of epoetin beta (EPOCH) in lung cancer (LC) patients with …

… in which epoetin was administered 150 U/kg thrice weekly. … , 17 of them under epoetin alpha
and the rest with epoetin beta. It … 320 patients who were diagnosed with lung cancer under …

… The pharmacokinetics (PK) of darbepoetin alfa have been … : (A) patients with lung cancer
receiving chemotherapy21 and … 30,000 to 40,000 IU per week of epoetin alfa or epoetin beta. …

… μg/kg weekly. Due to observed imbalances in death across … CERA; methoxy polyethylene
glycol-epoetin beta) is a new agent … assessment of safety and pharmacokinetic profile of CERA …

… of epoetin beta administered three times weekly in patients … The pharmacokinetics of epoetin
beta have been studied for … were required by patients with non-small cell lung cancer in a …

… of the pharmacokinetics (PK), pharmacodynamics (PD), clinical … Of the patients included,
40% had lung cancer, 13% had … , epoetin beta is approved for use in a 30,000 IU once-weekly …

… epoetin Beta and darbopoetin Alfa). New concepts for the cure of erythropoietin in cancer
patients include 3 and 4 weekly … in lung cancer patients receiving chemotherapy, J Nat1 cancer …

… pharmacokinetics and pharmacodynamics of endogenous and recombinant human
erythropoietin … observed in our patients, both lasting approximately 1 week. A study in sheep …